Shanghai Bio-heart Biological Technology Co (HKSE:02185) Total Liabilities : HK$41.21 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Total Liabilities?

Shanghai Bio-heart Biological Technology Co's Total Liabilities for the quarter that ended in Jun. 2024 was HK$41.21 Mil.

Shanghai Bio-heart Biological Technology Co's quarterly Total Liabilities declined from Jun. 2023 (HK$63.77 Mil) to Dec. 2023 (HK$48.17 Mil) and declined from Dec. 2023 (HK$48.17 Mil) to Jun. 2024 (HK$41.21 Mil).

Shanghai Bio-heart Biological Technology Co's annual Total Liabilities declined from Dec. 2021 (HK$98.01 Mil) to Dec. 2022 (HK$74.23 Mil) and declined from Dec. 2022 (HK$74.23 Mil) to Dec. 2023 (HK$48.17 Mil).

Shanghai Bio-heart Biological Technology Co Total Liabilities Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co Total Liabilities Chart

Shanghai Bio-heart Biological Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

48.76

98.01

74.23

48.17

56.85

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial						74.23	63.77	48.17	41.21	56.85

Shanghai Bio-heart Biological Technology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Bio-heart Biological Technology Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.951	+	(0.2	+	26.021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	48.17

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	894.601	-	846.428
	=	48.17

Shanghai Bio-heart Biological Technology Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.624	+	(0.172	+	25.417
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	41.21

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	843.811	-	802.598
	=	41.21

Shanghai Bio-heart Biological Technology Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Bio-heart Biological Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

http://www.bio-heart.com

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Executives

Tpg Operating Group Ii, L.p.	2201 Interest of corporation controlled by you
Chen Hao	2201 Interest of corporation controlled by you
Zhu Linan	2201 Interest of corporation controlled by you
Wang Nengguang	2201 Interest of corporation controlled by you
Union Season Holdings Limited	2201 Interest of corporation controlled by you
Sk China Company Limited	2201 Interest of corporation controlled by you
Right Lane Limited	2201 Interest of corporation controlled by you
Proud Solar Limited	2201 Interest of corporation controlled by you
Magic Grace Limited	2101 Beneficial owner
Loft Success Investments Limited	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p.	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited	2201 Interest of corporation controlled by you
Lc Fund Gp Limited	2201 Interest of corporation controlled by you
Great Unity Fund I, L.p.	2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines